ReviewClinical kidney journal2021
Preventive strategies for acute kidney injury in cancer patients.
Review in Clinical kidney journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 44 citations in OpenAlex.
- A tri-scale in silico framework integrating pharmacovigilance and mechanistic modeling suggests tepotinib-associated acute kidney injury risk.Renal failure · 2026Article
- Prediction of Acute Kidney Injury in Oncology: From Clinical Risk Scores to AI-Enabled Precision Onco-Nephrology.Cancers · 2026Review
- Review
- Article
- The Impact of Aspirin Use on In-Hospital Outcomes and Metastatic Disease in Colorectal Cancer: An Evaluation of the National Inpatient Sample.Journal of clinical medicine · 2026Article
- Acute Kidney Injury in Hospitalized Cancer Patients: Single-Centre Real-Life Analysis of Incidence and Clinical Impact.Journal of clinical medicine · 2026Article
- MRI andEndocrine oncology (Bristol, England) · 2026Article
- Early Acute Kidney Injury and Its Association With Survival in Patients With Metastatic Non-Small-Cell Lung Cancer Treated With Front-Line Immunotherapy-Based Therapies.Cancer medicine · 2025Article
- Updating Predictive Model for Cisplatin-Induced Acute Kidney Injury: Incorporating Concomitant Medications and the Standard Supportive Care.International journal of nephrology · 2025Article
- Fe-flavonoid nanozyme as dual modulator of oxidative stress and autophagy for acute kidney injury repair.Theranostics · 2025Article
- How to manage the dose of drugs in cancer patients with acute kidney injury, practical recommendations.International journal of clinical pharmacy · 2024Article
- Pan-cancer analyses of the associations between 109 pre-existing conditions and cancer treatment patterns across 19 adult cancers.Scientific reports · 2024Article
- Article
- Tumor Markers as Predictors of Acute Kidney Injury Incidence and Staging of the Muscle-Invasive Bladder Cancer Receiving Chemoradiation Therapy.World journal of oncology · 2023Article
- Surufatinib-induced renal thrombotic microangiopathy: first case report and review of literature.Virchows Archiv : an international journal of pathology · 2023Review
- Redox Regulation of Nrf2 in Cisplatin-Induced Kidney Injury.Antioxidants (Basel, Switzerland) · 2023Review
- The Onco-Nephrology Field: The Role of Personalized Chemotherapy to Prevent Kidney Damage.Cancers · 2023Review
- Changes in zinc and manganese concentrations in cisplatin-induced acute kidney injury.Biochemistry and biophysics reports · 2023Article
- Biopsy-proven acute tubulointerstitial nephritis in patients treated with immune checkpoint inhibitors: a pooled analysis of case reports.Frontiers in oncology · 2023Article
- Molecular Mechanisms and Biomarkers Associated with Chemotherapy-Induced AKI.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI) is a common complication of cancer that occurs in up to 50% of neoplastic patients during the natural history of their disease; furthermore, it has a huge impact on key outcomes such as overall prognosis, length of hospitalization and costs. AKI in cancer patients has different causes, either patient-, tumour- or treatment-related. Patient-related risk factors for AKI are the same as in the general population, whereas tumour-related risk factors are represented by compression, obstruction, direct kidney infiltration from the tumour as well by precipitation, aggregation, crystallization or misfolding of paraprotein (as in the case of multiple myeloma). Finally, treatment-related risk factors are the most common observed in clinical practice and may present also with the feature of tumour lysis syndrome or thrombotic microangiopathies. In the absence of validated biomarkers, a multidisciplinary clinical approach that incorporates adequate assessment, use of appropriate preventive measures and early intervention is essential to reduce the incidence of this life-threatening condition in cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.